Aspergillosis
MONDO:0005657Aspergillosis is an infection, growth, or allergic response caused by the Aspergillus fungus. There are several different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA), a condition where the fungus causes allergic respiratory symptoms similar to asthma, such as wheezing and coughing, but does not actually invade and destroy tissue. Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with weakened immune systems due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells. In this condition, the fungus invades and damages tissues in the body. Invasive aspergillosis most commonly affects the lungs, but can also cause infection in many other organs and can spread throughout the body (commonly affecting the kidneys and brain). Aspergilloma, a growth (fungus ball) that develops in an area of previous lung disease such as tuberculosis or lung abscess, is a third kind of aspergillosis. This type of aspergillosis is composed of a tangled mass of fungus fibers, blood clots, and white blood cells. The fungus ball gradually enlarges, destroying lung tissue in the process, but usually does not spread to other areas.
57 clinical trials for this condition and its sub-types, 20 tagged with Aspergillosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Aspergillosis
-
Pulmonary aspergilloma 11 trials · 38 incl. sub-types
2 sub-types
- Invasive aspergillosis 31 trials
- Malt worker's lung 0 trials
-
Allergic bronchopulmonary aspergillosis 15 trials
1 sub-type
- Malt worker's lung 0 trials
-
Neuroaspergillosis 1 trial
-
Aspergillus niger infection 0 trials
-
Two antifungal pills go head to head against a fungus that scars the lungs
Disease control Not yet recruitingResearchers compare two oral antifungal medicines, itraconazole and posaconazole, in people with chronic pulmonary aspergillosis, a fungal infection that damages the lungs over time. The trial enrolls 220 adults who have not yet received antifungal treatment and assigns them to o…
Phase 3 • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New study aims to improve inhaler treatment for lung fungus
Knowledge-focused Not yet recruitingThis study looks at how well an inhaled antifungal drug (liposomal amphotericin B) reaches the lungs in people with chronic pulmonary aspergillosis, a long-term lung infection. About 18 adults will inhale two different doses on separate days and then have special scans to see whe…
Phase 1 • Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Scientists hunt for clues to Drug-Resistant fungus in Patients' homes and workplaces
Knowledge-focused Not yet recruitingThis study will analyze respiratory samples from 1,000 patients in France to understand why some Aspergillus fungi become resistant to common antifungal drugs. Researchers will test samples for resistance and collect information about patients' environments, jobs, and medication …
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC